share_log

海利生物(603718.SH):拟调整认购上海润瓴并购基金份额

Shanghai Hile Bio-Technology (603718.SH): planning to adjust the subscription of shares in the Shanghai Runling M&A Fund.

Gelonghui Finance ·  Dec 23, 2024 15:39

Gelonghui reported on December 23 that Shanghai Hile Bio-Technology (603718.SH) announced that it has recently received a change notice from Wuxi Haoling Investment Management Partnership (Limited Partnership) (referred to as "Wuxi Haoling"), the general partner, executive partner, and fund manager of the Shanghai Runling M&A Fund. The total subscribed capital of the Shanghai Runling M&A Fund is proposed to be adjusted from 650 million yuan to 122.7 million yuan. Given that the Shanghai Runling M&A Fund has now entered the exit period and considering changes in various factors such as policies and regulations, market environment, and industry cycles, as well as based on Article 3.3.7 of the partnership agreement, which states that 'the general partner may decide to reduce the total subscribed capital of this limited partnership and stop accepting subsequent investments, but the total subscribed capital must not be lower than 30 million yuan,' Wuxi Haoling, as the general partner, executive partner, and fund manager of the Shanghai Runling M&A Fund, has notified all partners to reduce the total subscribed capital of the Shanghai Runling M&A Fund from 650 million yuan to 122.7 million yuan.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment